Search results
Results from the WOW.Com Content Network
This is a list of investigational aggression drugs, or drugs that are currently under development for clinical use in the treatment of aggression but are not yet approved. Drugs used to treat aggression may also be known as "serenics". [1] Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Toripalimab (Loqtorzi) is a humanized IgG4 monoclonal antibody against PD-1 approved in China in 2018 and in the United States in 2023. [18] [19] [20] Tislelizumab (Tevimbra) is a humanized IgG4 anti–PD-1 monoclonal antibody approved in China in 2019 and in the United States in 2024 for certain gastrointestinal cancers.
It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and Hodgkin's lymphoma. [16] Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17]
A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law requiring pharmaceutical companies to negotiate drug prices with the ...
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required, by section 202 of that Act, for substances to be placed in this schedule: The drug or other substance has a high potential for abuse.
A U.S. appeals court on Wednesday ruled that a pot-smoking gun owner in Texas cannot be prosecuted for violating a federal ban on users of illegal drugs owning firearms, saying it is ...
(Reuters) -A U.S. appeals court on Friday refused to block a federal mandate requiring health insurers to cover preventive care services like cancer screenings and HIV-preventing medication at no ...